ArticleCureus2025
Sudden Death Due to Hypercoagulability in a Patient With Pancreatic Cancer and Diabetic Ketoacidosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a significant contributor to cancer-related mortality, with an increasing incidence linked to an aging population. A rare complication of pancreatic cancer is diabetic ketoacidosis (DKA), which arises from the tumor's impairment of insulin production. DKA can also present alongside other challenges such as malnutrition and hypercoagulability. This study describes a 67-year-old female patient with a past medical history of type 2 diabetes who presented with DKA and was later diagnosed with a pancreatic mass suggestive of malignancy. She developed multiple venous thrombi and subsequent pulmonary emboli, leading to sudden death. Autopsy revealed extensive occlusive thrombi and ischemic changes, emphasizing the potentially life-threatening interactions between DKA, malignancy-associated hypercoagulability, and metabolic derangements of pancreatic cancer. This study reinforces the need for careful monitoring and management of thrombotic events in patients with multiple comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.